Scott Bluni is an experienced intellectual property attorney focused on counseling clients in patent-related matters such as strategic portfolio development, infringement avoidance, due diligence, enforcement, licensing, and other technology transactions. Dr. Bluni leverages his experiences as a former patent examiner and chief intellectual property counsel at a large, international medtech corporation to bring a pragmatic, solution-based approach to his practice.
Dr. Bluni has been recognized by Chambers USA: America’s Leading Lawyers for Business, Super Lawyers Massachusetts, LMG Life Sciences, and Managing IP – IP Stars.
The George Washington University Law School
PhDMaterials Science and Engineering1994
MSMaterials Science and Engineering1992
- New Hampshire
- New York
- U.S. Patent and Trademark Office (USPTO)
Recognition & Awards
Dr. Bluni has received numerous recognitions including a Chambers Band 4 IP Attorney ranking (2017-2023); Super Lawyers Massachusetts (2020-2021); America’s Leading Lawyers For Business: Massachusetts; Managing IP: Global IP Star (2018), Legal 500 US for Patents: Prosecution (2023); and LMG Life Sciences: Life Sciences Star.
Chambers USA recognizes Dr. Bluni as “extremely hard-working and responsive,” and having "fantastic practical business instincts as well as strong legal skills.”
Dr. Bluni’s publications include:
- Author, “CareDx v. Natera: The Latest in Patent Eligibility of Medical Diagnostics,” IP Watchdog, October 13, 2021
- Co-Author, “Understanding Medical Diagnostic Method Patent Eligibility,” Med Device Online, July 31, 2019
- Co-Author, “Mission Product Oral Argument Promises Certainty on Long Unresolved Question,” IPWatchdog, February 25, 2019